Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 86366E106 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
13.2% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 13.2% | |||
| Abigail P. Johnson | 13.2% | |||
|
Wellington Management Group LLP
13G/A
|
10.1% |
2/10/2026
Event 12/31/2025
|
||
| Wellington Management Group LLP | 10.1% | |||
| Wellington Group Holdings LLP | 10.1% | |||
| Wellington Investment Advisors Holdings LLP | 10.1% | |||
| Wellington Management Company LLP | 9.6% | |||
|
Avoro Capital Advisors LLC
13G
|
9.4% |
11/14/2025
Event 9/30/2025
|
||
| Avoro Capital Advisors LLC | 9.4% | |||
| Aghazadeh Behzad | 9.4% | |||
| Janus Henderson Group PLC 13G/A | 7.7% |
11/14/2025
Event 9/30/2025
|
||
|
Deep Track Capital, LP
13G/A
|
6.0% |
2/13/2026
Event 12/31/2025
|
||
| Deep Track Capital, LP | 6.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 6.0% | |||
| David Kroin | 6.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Biotechnology Value Fund L P
13G/A
|
4.9% |
2/17/2026
Event 12/31/2025
|
||
| Biotechnology Value Fund L P | 2.6% | |||
| BVF I GP LLC | 2.6% | |||
| Biotechnology Value Fund II LP | 1.9% | |||
| BVF II GP LLC | 1.9% | |||
| Biotechnology Value Trading Fund OS LP | 0.3% | |||
| BVF Partners OS Ltd. | 0.3% | |||
| BVF GP Holdings LLC | 4.5% | |||
| BVF Partners L P/IL | 4.9% | |||
| BVF Inc/IL | 4.9% | |||
| Lampert Mark N | 4.9% | |||
| Capital Research Global Investors 13G/A | 3.8% |
5/13/2025
Event 3/31/2025
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 32.3 k | $1.01 M |
| 2026 Q2 | 201 | 67.6 M | $3.62 B |
| 2026 Q1 | 212 | 67.0 M | $3.23 B |
| 2025 Q4 | 213 | 65.8 M | $4.58 B |
| 2025 Q3 | 176 | 56.7 M | $1.58 B |
| 2025 Q2 | 191 | 54.7 M | $1.13 B |
| 2025 Q1 | 168 | 56.0 M | $981 M |
| 2024 Q4 | 189 | 60.7 M | $1.65 B |
| 2024 Q3 | 181 | 61.6 M | $2.70 B |
| 2024 Q2 | 201 | 60.5 M | $2.38 B |
| 2024 Q1 | 150 | 44.3 M | $1.89 B |
| 2023 Q4 | 143 | 43.3 M | $1.77 B |
| 2023 Q3 | 86 | 32.8 M | $1.64 B |
| 2023 Q2 | 49 | 17.6 M | $699 M |
| 2023 Q1 | 40 | 14.8 M | $346 M |